Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Bosentan (Geropharm) vs Tracleer
NCT04101370Phase 1Completed
- Sponsor
- Geropharm
- Start
- May 2018
- Primary completion
- Jun 2018
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bosentan in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Geropharm. Primary endpoints: Maximum Plasma Concentration and Area Under the Concentration-Time Curve from Time Zero to Last Quantifiable Concentration. Started May 2018; status: completed.
02
Drugs
bosentan
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04101370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04101370.